Global Age-Related Macular Degeneration Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In November 2022, IVERIC bio, Inc. submitted the first part of its NDA to the US FDA for a rolling review of avacincaptad pegol a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

• In November 2022, The European Commission granted marketing authorization for Ximluci, the third ranibizumab biosimilar to be approved in the European Union. The product was developed through a partnership between STADA Arzneimittel and Xbrane Biopharma and is expected to launch in early 2023.

The global age-related macular degeneration (AMD) therapeutics market is segmented by drug type, disease indication, distribution channel, and geography. By drug type, the market includes key therapies such as ranibizumab, aflibercept, bevacizumab, pegaptanib, and brolucizumab, alongside others. These drugs, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, target abnormal blood vessel growth and leakage in the retina, effectively managing wet AMD and preventing vision loss. Innovations in these therapies, including longer-acting formulations, are driving advancements in treatment outcomes.

By disease indication, the market is divided into dry AMD (dAMD) and wet AMD (wAMD). While wet AMD represents the primary focus of pharmaceutical interventions due to its aggressive progression and significant visual impairment, research efforts are intensifying to address the unmet needs in managing dry AMD. Emerging therapies aim to slow retinal degeneration and offer neuroprotection, catering to the larger patient pool affected by dry AMD.

The distribution of these therapeutics spans hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies remain a vital channel for administering injectable treatments like anti-VEGF drugs, especially for patients requiring regular clinical monitoring. Retail pharmacies and online platforms enhance accessibility, particularly for oral medications or adjunctive therapies. Geographically, the market spans North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America, with regional growth influenced by healthcare infrastructure, prevalence rates, and patient awareness. Together, these factors shape a dynamic market landscape, fostering innovation and improved care for AMD patients worldwide.

Global Age-Related Macular Degeneration Therapeutics Segment Analysis

In this report, the Global Age-Related Macular Degeneration Therapeutics Market has been segmented by Disease Indication, Distribution Channel and Geography.

Global Age-Related Macular Degeneration Therapeutics Market, Segmentation by Drug Type

The Global Age-Related Macular Degeneration Therapeutics Market has been segmented by Drug Type into Ranibizumab, Aflibercept, Bevacizumab, Pegaptanib, Brolucizumab, and Others.

Ranibizumab, an anti-vascular endothelial growth factor (anti-VEGF) therapy, is widely used to treat wet AMD by inhibiting the growth of abnormal blood vessels in the retina, helping to prevent further vision loss. Aflibercept is another potent anti-VEGF agent, often prescribed for wet AMD and diabetic eye diseases, and is known for its longer dosing intervals compared to other therapies. Bevacizumab, originally developed for cancer treatment, is also used off-label for wet AMD, offering a cost-effective alternative to other anti-VEGF drugs.

Pegaptanib, a pegylated aptamer, was one of the first drugs approved for wet AMD treatment, though it is now less commonly used due to the development of more effective therapies like ranibizumab and aflibercept. Brolucizumab, a newer anti-VEGF therapy, is gaining traction for its ability to provide longer-lasting effects, reducing the frequency of injections needed for AMD patients. The "others" category includes emerging treatments and experimental drugs in the pipeline, targeting different aspects of AMD pathophysiology, including therapies aimed at retinal regeneration or neuroprotection.

This diversity in drug types reflects the ongoing evolution of AMD treatment, with a focus on improving patient outcomes through more effective, convenient, and long-acting therapies. Advances in drug formulations continue to drive innovation in the market, offering patients tailored treatment options based on their specific needs and the severity of their condition.

Global Age-Related Macular Degeneration Therapeutics Market, Segmentation by Disease Indication

The Global Age-Related Macular Degeneration Therapeutics Market has been segmented by Disease Indication into Dry Age-Related Macular Degeneration (dAMD), and Wet Age-Related Macular Degeneration (wAMD).

The Global Age-Related Macular Degeneration (AMD) Therapeutics Market is strategically segmented by disease indication, distinguishing between Dry Age-Related Macular Degeneration (dAMD) and Wet Age-Related Macular Degeneration (wAMD). This segmentation reflects the distinct pathophysiological mechanisms and clinical characteristics associated with each form of the disease. dAMD, the more prevalent subtype, is characterized by the gradual accumulation of drusen and atrophy of retinal pigment epithelium, leading to progressive vision loss. In contrast, wAMD involves abnormal growth of blood vessels beneath the retina, leading to rapid and severe vision impairment if left untreated. This targeted segmentation facilitates the development of tailored therapeutic approaches that address the specific needs and challenges associated with each subtype, ultimately optimizing patient outcomes.

Therapeutic strategies for Dry AMD primarily focus on disease management and lifestyle interventions aimed at slowing disease progression and preserving remaining vision. While no curative treatments exist for dAMD, ongoing research efforts are exploring innovative modalities such as complement inhibition and neuroprotection to address the underlying pathophysiology and mitigate vision loss. In contrast, the treatment landscape for Wet AMD has been revolutionized by the advent of anti-vascular endothelial growth factor (anti-VEGF) therapies, which effectively target the aberrant angiogenesis underlying the disease. These targeted therapies have demonstrated remarkable efficacy in stabilizing or improving vision outcomes for patients with wAMD, underscoring the importance of early diagnosis and prompt intervention in optimizing treatment efficacy.

As the global population continues to age, the prevalence of AMD is expected to rise significantly, driving the demand for innovative therapeutics to address this growing public health challenge. The segmentation of the AMD therapeutics market by disease indication not only facilitates precision medicine approaches but also fosters greater alignment between therapeutic development efforts and the diverse clinical needs of affected individuals. By leveraging this targeted segmentation, stakeholders can advance the development of novel treatment modalities, enhance patient access to tailored therapies, and ultimately mitigate the socioeconomic burden of AMD on healthcare systems worldwide.

Global Age-Related Macular Degeneration Therapeutics Market, Segmentation by Distribution Channel

The Global Age-Related Macular Degeneration Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

The segmentation of the Global Age-Related Macular Degeneration (AMD) Therapeutics Market by distribution channel offers insights into the diverse avenues through which patients access essential medications and supportive care products. Hospital Pharmacies serve as key points of dispensation for specialized AMD treatments, particularly for patients requiring intravitreal injections or surgical interventions. These pharmacies are equipped with the expertise and infrastructure necessary to handle complex therapeutic regimens and provide comprehensive patient care, ensuring optimal treatment outcomes for individuals with AMD.

Retail Pharmacies play a pivotal role in extending access to AMD therapeutics to the broader community, offering convenience and accessibility to patients seeking over-the-counter supplements, prescription medications, and supportive care products. With their widespread presence and extended operating hours, retail pharmacies cater to the diverse needs of AMD patients, providing personalized counseling and guidance on medication use, adherence, and lifestyle modifications. Additionally, retail pharmacies serve as hubs for health promotion and disease prevention, offering educational resources and screening programs to raise awareness about AMD and its management.

The emergence of Online Pharmacies has transformed the landscape of AMD therapeutics distribution, offering patients the convenience of procuring medications and healthcare products from the comfort of their homes. Online pharmacies provide a seamless platform for ordering prescription refills, accessing informational resources, and connecting with healthcare professionals remotely. This digital channel enhances patient convenience, particularly for individuals with mobility limitations or those residing in underserved rural areas. Moreover, online pharmacies facilitate greater transparency and price competitiveness, empowering patients to make informed decisions about their treatment options and healthcare spending. As the demand for AMD therapeutics continues to grow, leveraging the diverse distribution channels available will be essential to ensure equitable access to medications and comprehensive patient care across diverse populations.

Global Age-Related Macular Degeneration Therapeutics Market, Segmentation by Geography

In this report, the Global Age-Related Macular Degeneration Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Age-Related Macular Degeneration Therapeutics Market Share (%), by Geographical Region, 2024

The segmentation of the Global Age-Related Macular Degeneration (AMD) Therapeutics Market by geography into five distinct regions offers a comprehensive understanding of regional dynamics and market trends shaping the landscape of AMD treatment worldwide. North America, as a mature market for healthcare innovation, commands a significant share of the global AMD therapeutics market, driven by robust research infrastructure, high healthcare expenditure, and a rapidly aging population. The region's advanced healthcare systems and regulatory frameworks facilitate the adoption of novel therapeutic interventions and personalized treatment approaches for AMD patients.

In Europe, the AMD therapeutics market is characterized by a diverse healthcare landscape, encompassing both well-established pharmaceutical markets and emerging economies. The region's emphasis on universal healthcare coverage and patient-centric care models fosters equitable access to AMD treatments, while stringent regulatory standards ensure the safety and efficacy of therapeutic interventions. Moreover, collaborative initiatives between academia, industry, and healthcare providers drive innovation and research advancements in AMD management across Europe.

The Asia Pacific region presents immense growth opportunities for the AMD therapeutics market, fueled by rising healthcare spending, expanding patient populations, and increasing awareness of age-related eye diseases. Rapid urbanization and lifestyle changes contribute to the growing prevalence of AMD in countries such as China, India, and Japan, driving demand for innovative treatment modalities and supportive care solutions. Furthermore, strategic collaborations between multinational pharmaceutical companies and local stakeholders facilitate technology transfer, knowledge exchange, and capacity building, thereby accelerating the pace of therapeutic innovation and market expansion in the Asia Pacific region. As the global burden of AMD continues to escalate, strategic investments in research, infrastructure, and healthcare delivery systems are essential to address the unmet needs of AMD patients across diverse geographic regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Age-Related Macular Degeneration Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Aging Population
• Increasing Disease Prevalence

• Rising Healthcare Expenditure - Rising healthcare expenditure represents a significant driver of growth and innovation within the Global Age-Related Macular Degeneration (AMD) Therapeutics Market. As economies worldwide witness an increase in healthcare spending, particularly in developed regions like North America and Europe, greater investments are allocated towards research, development, and access to advanced treatments for age-related eye diseases. This heightened financial commitment enables the expansion of healthcare infrastructure, fostering the availability of specialized clinics, diagnostic facilities, and treatment centers equipped to address the growing prevalence of AMD.

  The rising healthcare expenditure facilitates greater patient access to innovative therapeutic interventions, including cutting-edge pharmacotherapies, surgical procedures, and regenerative medicine approaches. With a larger pool of financial resources allocated to healthcare, individuals affected by AMD can benefit from timely diagnosis, comprehensive disease management, and personalized treatment plans tailored to their unique clinical needs and preferences. Additionally, increased healthcare spending supports the training and education of healthcare professionals, ensuring a skilled workforce capable of delivering high-quality care to AMD patients across diverse settings.

  The growing financial commitment to healthcare fosters collaborations between industry stakeholders, research institutions, and regulatory bodies, driving innovation and technological advancements in AMD therapeutics. This collaborative ecosystem facilitates the translation of scientific discoveries into clinically meaningful interventions, accelerating the development and commercialization of novel treatment modalities for AMD. Ultimately, rising healthcare expenditure underscores the importance of prioritizing age-related eye diseases within global health agendas, advocating for equitable access to affordable and effective AMD therapies to mitigate the socioeconomic burden of vision loss on individuals and healthcare systems alike.

Restraints:

• High Treatment Costs
• Limited Access to Healthcare

• Lack of Awareness - The lack of awareness regarding age-related macular degeneration (AMD) presents a significant barrier to effective disease management and prevention. Despite being a leading cause of vision impairment and blindness among older adults worldwide, AMD often goes undetected or misdiagnosed due to limited public awareness and understanding of its symptoms and risk factors. This pervasive lack of awareness hampers early detection and timely intervention, resulting in delayed diagnosis and suboptimal treatment outcomes for individuals affected by AMD.

  The lack of awareness surrounding AMD contributes to misconceptions and stigma associated with the condition, hindering open communication and proactive engagement with healthcare providers. Many individuals may dismiss early signs of vision changes or attribute them to normal aging, thereby overlooking the importance of regular eye examinations and preventive measures to mitigate the progression of AMD. This lack of awareness perpetuates a cycle of underdiagnosis and undertreatment, exacerbating the socioeconomic burden of AMD on affected individuals, families, and healthcare systems.

  Addressing the lack of awareness regarding AMD requires multifaceted strategies that encompass public education, community outreach, and healthcare provider training. Initiatives aimed at raising awareness about the risk factors, symptoms, and consequences of AMD can empower individuals to prioritize their eye health, seek timely screenings, and adopt preventive measures such as lifestyle modifications and dietary interventions. Moreover, integrating AMD awareness campaigns into broader public health initiatives and healthcare delivery systems can enhance early detection efforts and facilitate timely referrals for specialized care, ultimately improving visual outcomes and quality of life for individuals living with AMD. By fostering a culture of awareness and proactive engagement, stakeholders can work collaboratively to reduce the prevalence and impact of AMD on global eye health.

Opportunities:

• Innovative Therapeutic Approaches
• Telemedicine and Remote Monitoring

• Patient Education and Awareness Programs - Patient education and awareness programs play a pivotal role in empowering individuals to take proactive steps towards managing and preventing age-related macular degeneration (AMD). These programs aim to equip patients with the knowledge and resources necessary to recognize the early signs and symptoms of AMD, understand their risk factors, and make informed decisions about their eye health. By raising awareness about the importance of regular eye examinations and preventive measures, such as lifestyle modifications and nutritional interventions, patient education programs empower individuals to prioritize their ocular health and seek timely medical intervention when needed.

  Patient education and awareness programs foster a supportive community where individuals affected by AMD can access valuable information, share experiences, and seek guidance from healthcare professionals and peers. These programs provide a platform for dialogue and collaboration, enabling patients to navigate the complexities of AMD diagnosis, treatment, and rehabilitation with confidence and resilience. By fostering a sense of solidarity and mutual support, patient education initiatives contribute to the holistic well-being of individuals living with AMD, fostering a culture of empowerment, resilience, and advocacy within the AMD community.

  Patient education and awareness programs serve as catalysts for positive behavior change and health-seeking attitudes among individuals at risk of AMD. By disseminating evidence-based information and practical strategies for AMD prevention and management, these programs empower individuals to adopt healthy lifestyle habits, such as smoking cessation, regular exercise, and balanced nutrition, which can mitigate their risk of developing AMD or slow its progression. By leveraging targeted messaging, interactive resources, and community-based outreach, patient education programs can drive sustained engagement and adherence to recommended eye health practices, ultimately reducing the burden of AMD on affected individuals, families, and healthcare systems alike.